TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galapagos ( (GLPG) ) just unveiled an update.
On November 3, 2025, Galapagos NV announced that it will present new data for its CAR T-cell therapy candidate, GLPG5101, at the upcoming American Society of Hematology Annual Meeting in December 2025. The data, derived from Phase 2 studies, highlight the potential of GLPG5101 in treating relapsed/refractory non-Hodgkin lymphoma, demonstrating high complete response rates and low-grade toxicities. This development underscores Galapagos’ commitment to advancing cell therapy solutions and could enhance its positioning in the oncology market by addressing high unmet medical needs.
The most recent analyst rating on (GLPG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
Galapagos faces significant financial challenges, with negative profitability and cash flow issues being the most impactful factors. The technical analysis suggests a bearish trend, with potential for a reversal. Valuation metrics are weak due to negative earnings and lack of dividends, further impacting the overall score.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a biotechnology company focused on the development of cell therapy products, particularly in the field of oncology. The company is known for its innovative decentralized cell therapy manufacturing platform, which aims to deliver fresh, fit cells rapidly, improving patient outcomes and experiences.
Average Trading Volume: 230,294
Technical Sentiment Signal: Hold
Current Market Cap: $2.09B
Learn more about GLPG stock on TipRanks’ Stock Analysis page.